← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Cassava Sciences, Inc
Austin, TX
$20,138,549
Total funding
9
Grants
Funding over time
peak $5.9M · FY2006–21$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$20,138,549 · 9
By mechanism
R44$17,032,986 · 6
R01$2,710,220 · 1
R42$295,343 · 1
R43$100,000 · 1
Investigators at Cassava Sciences, Inc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Multiple Ascending Dose clinical trial of PTI-125, a novel AD therapeutic candidate$2,896,561
R44 · FY2019 · AG
Solid oral dosage form and chronic tox for PTI-125$2,896,320
R44 · FY2018 · AG
Food Effect study and drug supply scale-up for PTI-125$2,710,220
R01 · FY2021 · AG
Open-label extension of a 3-month blinded clinical trial of PTI-125$2,499,896
R44 · FY2020 · AG
Preformulation and formulation development of Fenrock, an Abuse-resistant Fentanyl Transdermal Patch$1,879,039
R44 · FY2019 · DA
IND- and NDA-enabling toxicology studies for PTI-125, a novel small molecule for Alzheimer's disease$1,500,000
R44 · FY2016 · AG
IND, FIH study and 3-month tox for PTI-125, a novel therapeutic for Alzheimer's disease$1,500,000
R44 · FY2017 · AG
Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease$1,109,748
R44 · FY2019 · AG
Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease$450,142
R44 · FY2020 · AG
Increasing size of Phase 2b clinical trial to 60 patients$374,500
R44 · FY2020 · AG
Extending clinical trial in AD patients from 1 to 3 months$374,500
R44 · FY2018 · AG
Additional costs related to formulation, chronic tox and general development of PTI-125$350,000
R44 · FY2018 · AG
Preformulation and formulation development of Fenrock, an Abuse-resistant Fentanyl Transdermal Patch$349,947
R44 · FY2017 · DA
Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease$295,343
R42 · FY2017 · AG
Multiple Ascending Dose clinical trial of PTI-125, a novel AD therapeutic candidate$260,585
R44 · FY2018 · AG
IND, FIH study and 3-month tox for PTI-125, a novel therapeutic for Alzheimer's disease$225,000
R44 · FY2017 · AG
IND- and NDA-enabling toxicology studies for PTI-125, a novel small molecule for Alzheimer's disease$225,000
R44 · FY2015 · AG
Additional bioanalytical, dose analysis and DSMB costs for PTI-125 development$141,748
R44 · FY2017 · AG
Abuse-deterrent sustained-release hydromorphone$100,000
R43 · FY2006 · DA